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Emergency admissions due to adverse drug reactions (ADRs) have markedly increased in England 
from 60 000 hospitalizations per year in 2008 to 92 000 hospitalizations in 2015. [1]These ADRs are 
estimated to cost £83.7 million per year, with projected loss of 627 lives.[2] More broadly, a meta-
analysis of 42 studies from across the world found that 8.7% of hospital admission in older people 
were due to ADRs. [3] In order to stem this tide, experts have emphasised the importance of de-
prescribing high-risk drugs in primary care to “reduce appreciably the number of preventable drug-
related admissions to hospital.” [4]  However, Elliott’s evidence synthesis has reported that some 
ADR admissions cannot be avoided. [2] Resource-intensive, mass pre-emptive screening may only be 
worthwhile if a substantial proportion of hospitalized patients actually have preventable drug-
related admissions. 
A wide range of tools or algorithms have therefore been developed to enable more precise 
prediction of ADR risk, and targeted identification of susceptible patients for medication review. 
Typically, the tools are in the form of different sets of predictor variables or markers (derived 
through expert consensus) for screening and surveillance of patients with potentially elevated risk of 
ADRs. Some ADR prediction tools can be used to summarize an overall risk score for an individual 
based on patient characteristics, laboratory findings and the entire drug history. Alternatively, many 
tools take the approach of assessing ADR risk related to specific drug classes in a clinical condition 
that renders the patient particularly susceptible. Examples of specific markers are aspirin use in 
patients with history of peptic ulcer (where patient is at risk of ADR of recurrent ulcer and bleeding), 
or beta-blockers in patient with asthma (where patient is at risk of ADR of worsening airway 
obstruction). [5] 
These surveillance sets of ADR predictor markers can be deployed in different ways through General 
Practitioner’s (GP) computer systems. Real-time alerts to warn of potential ADRs can be 
programmed (e.g. through clinical decision support systems) to pop up on the screen when GPs are 
seeing an individual patient who happens to trigger certain risk criteria. Conversely, a more formal 
approach, akin to surveillance or screening programmes, involves regular interrogation of the GP 
computer system for whole cohorts of patients who all share specific markers of ADR risk. Clinicians 
can run an electronic search of GP records, and then call back all those judged ‘at risk of ADR’ for 
targeted medication review and de-prescribing to reduce subsequent harm.  
Although both the above approaches seem eminently plausible, there are major issues with delivery 
and implementation into clinical practice.  First, is the (yet unproven) assumption that the chosen 
predictor variables are able to correctly and reliably distinguish cases who subsequently suffer ADRs 
from those who are unlikely to be harmed by ADRs. Here, we emphasise that the concept of 
‘potentially inappropriate or hazardous medication’ does not mean DEFINITELY inappropriate, nor 
that a harmful error has clearly occurred and must be rectified. Elliot’s review estimated that only 
1.7% of the prescribing errors in primary care would lead to serious harm, whereas the vast majority 
(98.3%) would have mild-moderate consequences for the health service[2].  We acknowledge that 
this classification is from a healthcare provider perspective and a patient may interpret the 
consequences to a different degree.  The researchers concluded that “Very few, or no data were 
found that indicated direct links between errors and harm, …., and what proportion of those errors 
reaching patients caused actual harm.” Similarly, a meta-analysis of 67 studies found only a modest 
association (Relative Risk 1.25, 95% Confidence Intervals 1.09 to 1.44) between ‘potentially 
inappropriate medications’ (as measured by tools such as Beers, or STOPP) and subsequent 
hospitalization with ADR. [6] 
Moreover, current pop-up alerts and predictive ADR markers are often blunt tools that simply flag 
up crude binary categories of ‘at-risk’ or ‘not at-risk’. The absence of any actual numerical estimate 
of harm is unhelpful. Both clinicians and patients need data regarding the specific ADR risk (whether 
it be say, 4%, or 10 %, or 50%) to make informed treatment choices, especially when trying to 
balance benefit of the drug against the harm. Clinicians may find it difficult to prioritize the highest-
risk individuals for urgent medication review because existing tools may not provide sufficient depth 
for personalized risk stratification amongst ‘at risk’ patients. 
We also recognize that the vast bulk of research on predictor variables has been based on studies of 
serious ADRs in hospitalized patients and are unlikely to be fully applicable to primary care.  The ADR 
predictor variables and tools derived from serious ADRs in hospitalized (tip of the iceberg) 
populations may not be generalizable to the wider community. There may exist a sizeable 
proportion of patients in primary care who suffer no serious harm from their medication (Figure 1) A 
computerized ADR prediction algorithm that is not well-validated in primary care could erroneously 
flagging up large chunks of low risk patients in the lower sections of Figure 1 because of low 
specificity and lack of understanding of clinical context. This, for instance may include prevalent 
users where the GP has made a clinical assessment that the particular drug is actually not risky for 
the individual. 
Prior to the deployment of any ADR tool, we must determine if the predictive markers of serious 
harm can or cannot perform accurately in a primary care setting. However, the available data on 
performance of ADR prediction tools is not reassuring. A systematic review of four ADR risk tools 
found that the discriminant ability was typically limited. [7] More recently, similarly disappointing 
results were obtained from evaluation of two different ADR prediction tools (including a newly 
derived tool incorporating STOPP/START items). [8]  False- positives and over-estimation of ADR 
harm are the most important problems for de-prescribing. Healthcare professionals may end up 
being very frustrated with poorly specific tools that generate a lot of additional burden and false 
alarms, whilst correctly predicting only small proportions of genuine ADRs. Patients can suffer 
unnecessary worry and inconvenience if they have been wrongly identified as being at risk of ADR. 
Moreover,  specific predictors that over-estimate risk of ADR may cause harm because beneficial 
drugs that are genuinely helping the patient are erroneously de-prescribed. 
Efficient use of scarce resources is also a key consideration, and a recently published model based on 
meta-analysis of primary care studies give us some important insights. If screening and de-
prescribing of inappropriate medicines succeeds in halving the number of inappropriate 
medications, between 3 or 4 ADR hospitalizations will be prevented for every 100 patients screened. 
[6] This translates to a number needed to screen of between 25 to 33.   Moreover, if each 
medication review requires 15 minutes of a GP or Pharmacist’s time, then they would have to set 
aside at least 8 hours of working time in their work schedule specifically for medication review tasks 
to prevent one ADR hospitalization. 
The preceding paragraphs clearly demonstrate that ADR prediction tools and algorithms cannot be 
considered as universally effective panaceas for tackling hazardous prescribing and ADRs. But what 
should we be doing instead? We believe that the first step should be to head back to the drawing 
board. The surveillance approach should be designed and tested in the same rigorous manner as any 
other screening procedure. Predictor variables for the ADR need to be obtained directly from 
population of interest e.g. primary care. We should ensure that these variables are available and 
reliably measured on the computer system where the tool or algorithm is deployed. Regularly 
updated and valid clinical information is particularly important for tools that utilize real time alerts. 
Once the predictor variables are assembled, the critical step is to then establish natural history in 
those who are predicted to be 'at-risk'. Does the tool correctly flag up the cohort of patients who 
suffer serious ADRs if no additional preventive action is taken? What proportions are true-positive 
and false-positive cases of ADR during follow-up? Here, obtaining an estimate of the Positive 
Predictive Value (PPV) is crucial to guiding clinical judgements on de-prescribing. In statistical terms, 
the PPV would be the probability of harm from ADR in those where the screening test flagged up as 
at risk i.e. of the people predicted by the screening tool/algorithm to be 'at risk' of ADR, what is the 
likelihood that they will genuinely be harmed?  Explicitly quantifying the performance of specific 
ADR markers in identifying ‘actual’ harm will help clinicians and patients prioritize their efforts 
towards the areas of greatest risk, and to avoid situations where there a lot of false alarms.  
Once the prognostic performance of the tool has been established, the next step is to develop and 
test de-prescribing interventions targeted at high-risk medications responsible for serious ADRs. The 
intervention should be evaluated in pragmatic randomized controlled trials to confirm feasibility, as 
well as effectiveness on hard patient outcomes, rather than just number of prescriptions. There 
must be a clear specification for outcome measurement of collateral damage from the intervention 
which should cover both psychological and physical harms, and resource use. Potential adverse 
effects of screening and de-prescribing should include capture of loss of disease control from 
stopping a beneficial drug, as well as adverse reactions from switching or adding other drugs from 
the medication review (e.g. diarrhoea from adding proton pump inhibitor to someone taking dual 
antiplatelet therapy). 
In summary, we feel that the time is not yet ready for computerized tools and algorithms to be used 
for de-prescribing and reducing ADRs. This is because the existing ADR prediction tools and 
algorithms do not have ability to synthesize clinical data to accurately estimate benefit-harm in 
individual patients. Although we strongly urge physicians to keep a constant daily focus on de-
prescribing, we cannot recommend implementation of any particular ADR prevention tool until we 
have robust and comprehensive studies that meet essential pre-requisites for effective screening 
programmes.  
Yes, it’s good to regularly review medications and stop drugs…but this should be carefully targeted 
at the scenarios where we are sure that the harms outweigh benefits, as well as cases where there is 
no tangible evidence of any benefit. 
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Figure 1 Hypothetical depiction of range of potential harm during follow-up of primary care patients 
that have been flagged up to be at risk of ADRs. 
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